Introduction a Chemical Weapon
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
This PDF Was Created from the British Library's Microfilm Copy of The
IMAGING SERVICES NORTH Boston Spa, Wetherby West Yorkshire, LS23 7BQ www.bl.uk This PDF was created from the British Library’s microfilm copy of the original thesis. As such the images are greyscale and no colour was captured. Due to the scanning process, an area greater than the page area is recorded and extraneous details can be captured. This is the best available copy THE BRITISH LIBRARY DOCUMENT SUPPLY CENTRE TITLE Synthesis and Biological Activities of a-aminoalkanephosphonic acids and a-aminoalkanephosphonous acids and their derivatives AUTHOR Fatima Bawa INSTITUTION and DATE The Polytechnic of North London, Attention is drawn to the fact that the copyright of this thesis rests with its author. This copy of the thesis has been supplied on condition that anyone who consults it is understood to recognise that its copyright rests with its author and that no information derived from it may be published without the author’s prior written consent THE BRITISH LIBRARY DOCUMENT SUPPLY CENTRE “ T* ~ n “T4I 1 II 1 II Bocton Spa, W atharty WaitYoffaMr« 20 cmt __L I 1 Unkad Kkifdoin RBOUCnONX'. The Polytechnic of North London in collaboration with Kenogard AB (Sweden) Synthesis and Biological Activities of a-aminoalkanephosphonic acids and a-amlnoalkanephosphonous acids and their derivatives by Fatima Bawa A thesis submitted for the Degree of Doctor of Philosophy of the Council for National Academic Awards. THE BRITISH LIBRARY DOCUMENT SUPPLY CENTRE BRITISH THESES NOT! C E The quality of this reproduction is heavily dependent upon the quality of the original thesis submitted for microfilming. Every effort has been made to ensure the highest quality of reproduction possible. -
Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts
Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4. -
MSM Cross Reference Antihistamine Decongestant 20100701 Final Posted
MISSISSIPPI DIVISION OF MEDICAID Antihistamine/Decongestant Product and Active Ingredient Cross-Reference List The agents listed below are the antihistamine/decongestant drug products listed in the Mississippi Medicaid Preferred Drug List (PDL). This is a cross-reference between the drug product name and its active ingredients to reference the antihistamine/decongestant portion of the PDL. For more information concerning the PDL, including non- preferred agents, the OTC formulary, and other specifics, please visit our website at www.medicaid.ms.gov. List Effective 07/16/10 Therapeutic Class Active Ingredients Preferred Non-Preferred ANTIHISTAMINES - 1ST GENERATION BROMPHENIRAMINE MALEATE BPM BROMAX BROMPHENIRAMINE MALEATE J-TAN PD BROMSPIRO LODRANE 24 LOHIST 12HR VAZOL BROMPHENIRAMINE TANNATE BROMPHENIRAMINE TANNATE J-TAN P-TEX BROMPHENIRAMINE/DIPHENHYDRAM ALA-HIST CARBINOXAMINE MALEATE CARBINOXAMINE MALEATE PALGIC CHLORPHENIRAMINE MALEATE CHLORPHENIRAMINE MALEATE CPM 12 CHLORPHENIRAMINE TANNATE ED CHLORPED ED-CHLOR-TAN MYCI CHLOR-TAN MYCI CHLORPED PEDIAPHYL TANAHIST-PD CLEMASTINE FUMARATE CLEMASTINE FUMARATE CYPROHEPTADINE HCL CYPROHEPTADINE HCL DEXCHLORPHENIRAMINE MALEATE DEXCHLORPHENIRAMINE MALEATE DIPHENHYDRAMINE HCL ALLERGY MEDICINE ALLERGY RELIEF BANOPHEN BENADRYL BENADRYL ALLERGY CHILDREN'S ALLERGY CHILDREN'S COLD & ALLERGY COMPLETE ALLERGY DIPHEDRYL DIPHENDRYL DIPHENHIST DIPHENHYDRAMINE HCL DYTUSS GENAHIST HYDRAMINE MEDI-PHEDRYL PHARBEDRYL Q-DRYL QUENALIN SILADRYL SILPHEN DIPHENHYDRAMINE TANNATE DIPHENMAX DOXYLAMINE SUCCINATE -
Nomenclature Worksheet Part 2-Binary Molecular Compounds
Nomenclature Worksheet Part 2-Binary Molecular Compounds. When two different elements combine, they form a binary compound. We have seen some ionic binary compounds such as sodium chloride, NaCl, or copper(II) oxide, CuO. But, non-metals can also form binary compounds, the most famous of which is water, H2O. We have learned how to name binary ionic compounds. In this worksheet, we will practice naming binary molecular compounds. Binary molecular compounds are held together by covalent bonds. As in ionic compounds, the more metallic element is listed first, and the less metallic is listed second. This coincides with the concept of electronegativity (and the converse, electropositivity) that we discussed in class. So, another way of stating this is the more electropositive element is written first followed by the more electronegative element. An example of this is SF6, Notice that sulfur is more electropositive than fluoride and is written first. If both elements are in the same group, the element with the higher period number goes first. We see this in the formulas of SO2 and IBr. Binary molecular compounds differ from ionic compounds in a key way: we can’t use charge to name the compound. So how will we distinguish CO2 from CO, NO2 from N2O? We will use need a different system from ionic nomenclature. In ionic nomenclature, we use charges and the position on the periodic table to indicate the number and types of ions in the compounds. The charges are whole numbers. Binary molecules can have fractional charges and multiple compounds for the combination of elements. -
Copyrighted Material
1 Historical Milieu 1.1 Organophosphorus Nerve Agents 2 1.2 Blister Agents 5 1.3 Sternutator Agents 11 1.4 Chemical Weapons Convention (CWC) 13 1.4.1 Schedule of Chemicals 14 1.4.2 Destruction of Chemical Weapons 14 References 16 COPYRIGHTED MATERIAL Analysis of Chemical Warfare Degradation Products, First Edition. Karolin K. Kroening, Renee N. Easter, Douglas D. Richardson, Stuart A. Willison and Joseph A. Caruso. © 2011 John Wiley & Sons, Ltd. Published 2011 by John Wiley & Sons, Ltd. 2 ANALYSIS OF CHEMICAL WARFARE DEGRADATION PRODUCTS 1.1 ORGANOPHOSPHORUS NERVE AGENTS Organophosphorus (OP) type compounds, that is, deriva- tives containing the P=O moiety, were first discovered in the 1800s when researchers were investigating useful applica- tions for insecticides/rodenticides. There are many derivatives of organophosphorus compounds, however, the OP deriva- tives that are typically known as ‘nerve agents’ were discov- ered accidentally in Germany in 1936 by a research team led by Dr. Gerhard Schrader at IG Farben [1–4]. Schrader had noticed the effects and lethality of these organophosphorus compounds towards insects and began developing a new class of insecticides. While working towards the goal of an improved insecticide, Schrader experimented with numerous phosphorus-containing compounds, leading to the discovery of the first nerve agent, Tabun (or GA) (Figure 1.1). The potency of these insecticides towards humans was not realized until there was yet another accident, which involved a Tabun spill. Schrader and coworkers began experiencing symptoms, such as miosis (constriction of the pupils of the eyes), dizziness and severe shortness of breath, with numerous effects lasting several weeks [1, 4, 5]. -
Brompheniramine Maleate, Pseudoephedrine Hydrochloride
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE, AND DEXTROMETHORPHAN HYDROBROMIDE- brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide syrup Morton Grove Pharmaceuticals, Inc. ---------- Brompheniramine Maleate, Pseudoephedrine Hydrochloride, and Dextromethorphan Hydrobromide Oral Syrup 2 mg/30 mg/10 mg per 5 mL Rx only DESCRIPTION Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Oral Syrup is a clear, light pink syrup with a butterscotch flavor. Each 5 mL (1 teaspoonful) contains: Brompheniramine Maleate, USP 2 mg Pseudoephedrine Hydrochloride, USP 30 mg Dextromethorphan Hydrobromide, USP 10 mg Alcohol 0.95% v/v In a palatable, aromatic vehicle. Inactive Ingredients: artificial butterscotch flavor, citric acid anhydrous, dehydrated alcohol, FD&C Red No. 40, glycerin, liquid sugar, methylparaben, propylene glycol, purified water and sodium benzoate. It may contain 10% citric acid solution or 10% sodium citrate solution for pH adjustment. The pH range is between 3.0 and 6.0. C16H19BrN2·C4H4O4 M.W. 435.31 Brompheniramine Maleate, USP (±)-2-p-Bromo-α-2-(dimethylamino)ethylbenzylpyridine maleate (1:1) C10H15NO · HCl M.W. 201.69 Pseudoephedrine Hydrochloride, USP (+)-Pseudoephedrine hydrochloride C18H25NO · HBr · H2O M.W. 370.32 Dextromethorphan Hydrobromide, USP 3-Methoxy-17-methyl-9α, 13α, 14α -morphinan hydrobromide monohydrate Antihistamine/Nasal Decongestant/Antitussive syrup for oral administration. CLINICAL PHARMACOLOGY Brompheniramine maleate is a -
CHEM 1000 Practice Final a (Answers)
1 Name: ________________________ Student Number: _____________________ Chemistry 1000 Practice Final Exam A Based on Fall 2009 Test (Content Updated to Fall 2012 Curriculum) INSTRUCTIONS 1) Read the exam carefully before beginning. There are 19 questions on pages 2 to 12 followed by 2 pages of “Data Sheet” (including periodic table) and a blank page for any rough work. Please ensure that you have a complete exam. If not, let an invigilator know immediately. All pages must be submitted at the end of the exam. 2) If your work is not legible, it will be given a mark of zero. 3) Marks will be deducted for incorrect information added to an otherwise correct answer. 4) You may use a calculator. 5) Show your work for all calculations. Answers without supporting calculations will not be given full credit. 6) Marks will be deducted for improper use of significant figures and for numerical answers with incorrect/missing units. 7) Do not open the exam until you are told to begin. Beginning prematurely will result in removal of your exam paper and a mark of 0. 8) You have 3 hours to complete this exam. Nobody may leave the exam room during the first hour or the last 15 minutes of the exam. Q Mark Q Mark 1 / 23 11 / 7 2 / 3 12 / 9 3 / 5 13 / 8 4 / 3 14 / 3 5 / 3 15 / 4 6 / 2 16 / 10 7 / 4 17 / 6 8 / 3 18 / 2 9 / 12 19 / 1 10 / 2 Total / 110 2 Name: ________________________ Student Number: _____________________ 1. -
Phosphorus and Sulfur Cosmochemistry: Implications for the Origins of Life
Phosphorus and Sulfur Cosmochemistry: Implications for the Origins of Life Item Type text; Electronic Dissertation Authors Pasek, Matthew Adam Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 07/10/2021 06:16:37 Link to Item http://hdl.handle.net/10150/194288 PHOSPHORUS AND SULFUR COSMOCHEMISTRY: IMPLICATIONS FOR THE ORIGINS OF LIFE by Matthew Adam Pasek ________________________ A Dissertation Submitted to the Faculty of the DEPARTMENT OF PLANETARY SCIENCE In Partial Fulfillment of the Requirements For the Degree of DOCTOR OF PHILOSOPHY In the Graduate College UNIVERSITY OF ARIZONA 2 0 0 6 2 THE UNIVERSITY OF ARIZONA GRADUATE COLLEGE As members of the Dissertation Committee, we certify that we have read the dissertation prepared by Matthew Adam Pasek entitled Phosphorus and Sulfur Cosmochemistry: Implications for the Origins of Life and recommend that it be accepted as fulfilling the dissertation requirement for the Degree of Doctor of Philosophy _______________________________________________________________________ Date: 04/11/2006 Dante Lauretta _______________________________________________________________________ Date: 04/11/2006 Timothy Swindle _______________________________________________________________________ Date: 04/11/2006 -
Toxicological Profile for Glyphosate Were
A f Toxicological Profile for Glyphosate August 2020 GLYPHOSATE II DISCLAIMER Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services. GLYPHOSATE III FOREWORD This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised and republished as necessary. The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced. The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's -
1 Abietic Acid R Abrasive Silica for Polishing DR Acenaphthene M (LC
1 abietic acid R abrasive silica for polishing DR acenaphthene M (LC) acenaphthene quinone R acenaphthylene R acetal (see 1,1-diethoxyethane) acetaldehyde M (FC) acetaldehyde-d (CH3CDO) R acetaldehyde dimethyl acetal CH acetaldoxime R acetamide M (LC) acetamidinium chloride R acetamidoacrylic acid 2- NB acetamidobenzaldehyde p- R acetamidobenzenesulfonyl chloride 4- R acetamidodeoxythioglucopyranose triacetate 2- -2- -1- -β-D- 3,4,6- AB acetamidomethylthiazole 2- -4- PB acetanilide M (LC) acetazolamide R acetdimethylamide see dimethylacetamide, N,N- acethydrazide R acetic acid M (solv) acetic anhydride M (FC) acetmethylamide see methylacetamide, N- acetoacetamide R acetoacetanilide R acetoacetic acid, lithium salt R acetobromoglucose -α-D- NB acetohydroxamic acid R acetoin R acetol (hydroxyacetone) R acetonaphthalide (α)R acetone M (solv) acetone ,A.R. M (solv) acetone-d6 RM acetone cyanohydrin R acetonedicarboxylic acid ,dimethyl ester R acetonedicarboxylic acid -1,3- R acetone dimethyl acetal see dimethoxypropane 2,2- acetonitrile M (solv) acetonitrile-d3 RM acetonylacetone see hexanedione 2,5- acetonylbenzylhydroxycoumarin (3-(α- -4- R acetophenone M (LC) acetophenone oxime R acetophenone trimethylsilyl enol ether see phenyltrimethylsilyl... acetoxyacetone (oxopropyl acetate 2-) R acetoxybenzoic acid 4- DS acetoxynaphthoic acid 6- -2- R 2 acetylacetaldehyde dimethylacetal R acetylacetone (pentanedione -2,4-) M (C) acetylbenzonitrile p- R acetylbiphenyl 4- see phenylacetophenone, p- acetyl bromide M (FC) acetylbromothiophene 2- -5- -
Medication Instructions for Allergy Patients
MEDICATION INSTRUCTIONS FOR ALLERGY PATIENTS Drugs which contain antihistamine or have antihistaminic effects can result in negative reactions to skin testing. As a result, it may not be possible to properly interpret skin test results, and testing may have to be repeated at a later date. While this list is extensive, it is NOT all inclusive (particularly of the various brand names). Discontinue ALL antihistamines including the following medications seven (7) days prior to skin testing (unless longer time specified): Antihistamines – Generic name (Brand name(s)): Cetirizine (Zyrtec, Zyrtec-D) Hydroxyzine (Vistaril, Atarax) Desloratadine (Clarinex) Levocetirizine (Xyzal) Fexofenadine (Allegra, Allegra-D) Loratadine (Claritin, Claritin-D, Alavert) Diphenhydramine (Aleve PM, Benadryl, Bayer P.M., Benylin, Contac P.M., Doans P.M, Excedrin PM, Legatrin P.M.. Nytol, Tylenol Nighttime, Unisom, Zzzquil) Chlorpheniramine (Aller-Chlor, Allerest, Alka Seltzer Plus, Chlor-Trimeton, Comtrex, Contac, Co-Pyronil, Coricidin, CTM, Deconamine, Dristan, Dura-tap, Naldecon, Ornade Spansules, Rondec, Sinutab, Teldrin, Triaminic, Triaminicin, Tylenol Allergy) Azatadine (Optimine, Trinalin) Doxylamine (Nyquil) Brompheniramine (Bromfed, Dimetane, Dimetapp) Meclizine (Antivert) Carbinoxamine (Clistin, Rondec) Pheniramine Clemastine (Tavist) Phenyltoloxamine (Nadecon) Cyclizine (Marezine) Promethazine (Phenergan) Cyprohepatidine (Periactin) (9 days) Pyrilamine (Mepyramine) Dexbrompheniramine (Drixoral) Quinacrine (Atabrine) Dexchlorpheniramine (Extendryl, Polaramine) -
A Toxicological Review of the Products of Combustion
HPA-CHaPD-004 A Toxicological Review of the Products of Combustion J C Wakefield ABSTRACT The Chemical Hazards and Poisons Division (CHaPD) is frequently required to advise on the health effects arising from incidents due to fires. The purpose of this review is to consider the toxicity of combustion products. Following smoke inhalation, toxicity may result either from thermal injury, or from the toxic effects of substances present. This review considers only the latter, and not thermal injury, and aims to identify generalisations which may be made regarding the toxicity of common products present in fire smoke, with respect to the combustion conditions (temperature, oxygen availability, etc.), focusing largely on the adverse health effects to humans following acute exposure to these chemicals in smoke. The prediction of toxic combustion products is a complex area and there is the potential for generation of a huge range of pyrolysis products depending on the nature of the fire and the conditions of burning. Although each fire will have individual characteristics and will ultimately need to be considered on a case by case basis there are commonalities, particularly with regard to the most important components relating to toxicity. © Health Protection Agency Approval: February 2010 Centre for Radiation, Chemical and Environmental Hazards Publication: February 2010 Chemical Hazards and Poisons Division £15.00 Chilton, Didcot, Oxfordshire OX11 0RQ ISBN 978-0-85951- 663-1 This report from HPA Chemical Hazards and Poisons Division reflects understanding and evaluation of the current scientific evidence as presented and referenced in this document. EXECUTIVE SUMMARY The Chemical Hazards and Poisons Division (CHaPD) is frequently required to advise on the health effects arising from incidents due to fires.